IRCT20200127046282N34
Not yet recruiting
Phase 1
Investigating the safety and efficacy of intradermal injection of autologous Nanofat and conditioned medium derived from Wharton jelly mesenchymal stem cells in the treatment of androgenic alopecia compared to Nanofat alone: a double-blind clinical trial study
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Hair loss.
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 10
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age between 18\-60
- •Patients who do not want to take or are allergic to minoxidil
Exclusion Criteria
- •Individuals who have used any product or medication during the previous 6 months that may affect hair growth
- •Pregnancy and breastfeeding
- •History of cancer
- •People with Mental Disorders
- •Active infection of the scalp
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
Investigating the safety and efficacy of injection of fat tissue cells in patients with sclerodermascleroderma.Systemic sclerosis [scleroderma]IRCT20200127046282N35Tehran University of Medical Sciences18
Not yet recruiting
Phase 2
Facial Pigmentation Treatment by Injection Tranexamic acid intradermally in skiHealth Condition 1: L811- ChloasmaCTRI/2022/02/040450Dr Meghna Khatri
Not yet recruiting
Phase 1
Assessment of the effect of exosomes in the treatment of melasmaIRCT20221130056672N6Tehran University of Medical Sciences30
Not yet recruiting
Not Applicable
Comparative study of Intradermal versus Intralesional Purified Protein Derivative (PPD) for treatment of common warts in childreHealth Condition 1: L088- Other specified local infections of the skin and subcutaneous tissueCTRI/2019/07/020070Himachal Pradesh University
Recruiting
Not Applicable
A study to compare efficacy of intradermal Tranexamic acid injections versus topical Tranexamic acid gel versus topical triple combination (Hydroquinone 2 %, Tretinion 0.025%, Flucinolone acetonide 0.01%) cream in patients suffering from melasmaCTRI/2017/07/009158MGM Medical COllege and Hospital180